Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 16, 2007. The report details a specific corporate action regarding a share repurchase authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 3,150,000 Ordinary shares.
- Purchase Price: 1,234.38 pence per share.
- Treasury Holdings: 362,412,158 shares (representing 6.34% of total voting rights).
- Shares in Issue: 5,659,804,888 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares and the increase in Treasury stock following the August 16 transaction. The total voting rights in the Company are now represented by the 5,659,804,888 shares in issue.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,659,804,888) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (362,412,158) and its impact on the 6.34% voting rights representation.
- Note that this filing does not contain financial performance data; refer to Form 20-F for revenue and profit metrics.